Tony Coles, Cerevel
Bain doubles down on Tony Coles’ quest to get a late-stage Parkinson’s drug through to market
Cerevel Therapeutics had a charmed start to its life with the backing of financial giant Bain Capital and a clutch of former Pfizer assets to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
